- Home
- CBU vs KNSA Comparison
CBU vs KNSA Comparison
Compare CBU & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CBU | KNSA |
|---|---|---|
| Founded | 1866 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.5B |
| IPO Year | 1994 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CBU | KNSA |
|---|---|---|
| Price | $62.80 | $52.72 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $66.67 | $58.43 |
| AVG Volume (30 Days) | 172.0K | ★ 742.4K |
| Earning Date | 04-29-2026 | 04-28-2026 |
| Dividend Yield | ★ 2.98% | N/A |
| EPS Growth | 15.41 | ★ 225.00 |
| EPS | ★ 3.97 | 0.27 |
| Revenue | ★ $818,007,000.00 | $677,564,000.00 |
| Revenue This Year | $13.46 | $37.48 |
| Revenue Next Year | $7.75 | $17.87 |
| P/E Ratio | ★ $15.96 | $71.19 |
| Revenue Growth | 9.61 | ★ 60.09 |
| 52 Week Low | $51.12 | $25.71 |
| 52 Week High | $67.50 | $54.23 |
Technical Indicators
Market Signals| Indicator | CBU | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 56.97 | 67.75 |
| Support Level | $60.17 | $40.67 |
| Resistance Level | $64.73 | N/A |
| Average True Range (ATR) | 1.25 | 2.18 |
| MACD | 0.04 | 0.70 |
| Stochastic Oscillator | 51.92 | 87.79 |
Price Performance
Historical ComparisonAbout CBU Community Bank System Inc.
Community Financial System Inc is a diversified financial services company providing a broad array of banking and other financial services to retail, commercial, institutional and governmental customers. The Company also offers comprehensive financial planning, trust administration and wealth management services through its Community Bank Wealth Management operating unit. It has four reportable operating business segments: Banking and Corporate, Employee Benefit Services, Insurance Services and Wealth Management Services.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.